Laddar...
SGLT-2 inhibitors and atrial fibrillation in the Food and Drug Administration adverse event reporting system
BACKGROUND: Sodium glucose cotransporter-2 inhibitors (SGLT2i) reduce the risk of heart failure and new data show they can prevent atrial fibrillation (AF). We examined the association between SGLT2i and AF in the Food and Drug Administration adverse event reporting system (FAERS). METHODS: We mined...
Sparad:
| I publikationen: | Cardiovasc Diabetol |
|---|---|
| Huvudupphovsmän: | , , , |
| Materialtyp: | Artigo |
| Språk: | Inglês |
| Publicerad: |
BioMed Central
2021
|
| Ämnen: | |
| Länkar: | https://ncbi.nlm.nih.gov/pmc/articles/PMC7879696/ https://ncbi.nlm.nih.gov/pubmed/33573667 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1186/s12933-021-01243-4 |
| Taggar: |
Lägg till en tagg
Inga taggar, Lägg till första taggen!
|